CRBP director exercises 1,060 options at $4.8, sells at $20.5

Corbus Pharmaceuticals (CRBP) director Anne Altmeyer reported an option exercise and same‑day sale.

Rhea-AI Filing Summary

Corbus Pharmaceuticals (CRBP) director Anne Altmeyer reported an option exercise and same‑day sale. On 10/20/2025, she exercised 1,060 stock options at $4.8 per share (code M) and sold 1,060 common shares at $20.5 (code S). After these transactions, she beneficially owned 6,191 common shares directly.

The filing notes a Rule 10b5‑1 trading plan adopted on 11/14/2024 governed the sale. It also states her holdings include 4,800 unvested RSUs granted on 05/30/2025 that vest 100% on the one‑year anniversary of grant. Following the exercise, 4,247 options remain outstanding, fully vested, at a $4.8 exercise price expiring on 09/26/2032.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Altmeyer Anne

Role Director

Sold 1,060 shs ($22K)

Approx. gross sale proceeds $22K

Approx. exercise cost $5K

Type	Security	Shares	Price	Value
Exercise	Stock options (right to buy)	1,060	$0.00	$0.00
Exercise	Common Stock, par value $0.0001 per share	1,060	$4.80	$5K
Sale	Common Stock, par value $0.0001 per share	1,060	$20.50	$22K

Holdings After Transaction: Stock options (right to buy) — 4,247 contracts (Direct); Common Stock, par value $0.0001 per share — 6,191 shares (Direct)

Footnotes (3)

1. F1. This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant.
2. F2. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.
3. F3. The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRBP director Anne Altmeyer report on Form 4?

On 10/20/2025, she exercised 1,060 options at $4.8 and sold 1,060 common shares at $20.5 the same day.

How many CRBP shares does the reporting person own after the transactions?

She beneficially owned 6,191 common shares directly after the reported transactions.

Was the CRBP share sale under a Rule 10b5-1 plan?

Yes. The sale was effected under a Rule 10b5‑1 trading plan adopted on 11/14/2024.

What equity awards are noted for the CRBP director?

Her holdings include 4,800 unvested RSUs granted on 05/30/2025, vesting 100% on the one‑year anniversary of grant.

What options remain after the CRBP transaction and their terms?

She holds 4,247 fully vested options at a $4.8 exercise price, expiring on 09/26/2032.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/21/2025 - 04:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altmeyer Anne

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	10/20/2025		M		1,060	A	$4.8	7,251(1)	D
Common Stock, par value $0.0001 per share	10/20/2025		S(2)		1,060	D	$20.5	6,191(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)(3)	$4.8	10/20/2025		M			1,060	(3)	09/26/2032	Common Stock	1,060	$0	4,247	D

Explanation of Responses:

1. This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant.

2. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.

3. The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

	/s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.